RxDoctor Payments Data

Michelle Ang Poland, MD

Family Medicine · Springdale, ARNPI 1952429680

Payments from drug & device makers

$561in general payments, 2019–2025

Across 17 payments — averaging $33.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$122
  • Intuitive Surgical$108
  • Astellas Pharma US Inc$102
  • Amgen$47
  • Novo Nordisk$36
  • AstraZeneca$33
  • plus $113 from 6 others

What the payments were for

  • Food & beverage$48186%
  • Education$8014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$561 in reported general payments places this provider in the 50th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$119,810
Medicare patients
291
Services billed
3,520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide200$217,324
OzempicSemaglutide126$132,187
EliquisApixaban111$113,336
JardianceEmpagliflozin85$67,375
Trelegy ElliptaFluticasone/Umeclidin/Vilanter41$32,197
LinzessLinaclotide31$27,327
XareltoRivaroxaban37$26,450
JanuviaSitagliptin Phosphate21$20,228
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$15,467
Stiolto RespimatTiotropium Br/Olodaterol Hcl14$15,145
Spiriva RespimatTiotropium Bromide19$14,561
Spiriva HandihalerTiotropium Bromide21$14,375
Tresiba Flextouch U-200Insulin Degludec22$13,399
MyrbetriqMirabegron16$12,988
SymbicortBudesonide/Formoterol Fumarate43$12,559

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$36$132,187126 claims
AstraZenecaSymbicort, Farxiga$33$21,60659 claims
Astellas Pharma US IncMyrbetriq$102$12,98816 claims
NovartisEntresto$122$9,25214 claims
Sumitomo Pharma America, Inc.Gemtesa$17$5,86312 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Springdale

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →